https://www.selleckchem.com/pr....oducts/Gefitinib.htm
ications are satisfactory results. We wanted to share our small group of patients and their results in the hope of expanding the ketogenic diet. Regorafenib is a key agent for patients with advanced or recurrent colorectal cancer. Sarcopenia represented by skeletal muscle depletion is closely related to frailty and predicts oncological prognoses. We hypothesized that sarcopenia negatively affects the time to treatment failure (TTF) or overall survival (OS) of patients treated with regorafenib. We retrospectively reviewed the medical r
Like
Comment
Share
